Richard A. King
Directeur Général chez Prolynx LLC
Profil
Richard A.
King is currently the Chief Executive Officer & Director at Prolynx LLC since 2022.
He previously served as the Chief Executive Officer at Talphera, Inc. from 2014 to 2015, Chief Executive Officer & Director at Spruce Biosciences, Inc. from 2019 to 2021, President & General Manager at Tercica, Inc. in 2009, Executive Vice President-Commercial Operations at KOS Pharmaceuticals, Inc. from 2002 to 2006, Senior Vice President-Commercial Operations at Solvay Pharmaceuticals, Inc. from 2000 to 2002, and Chief Operating Officer at Adamas Pharmaceuticals LLC from 2017 to 2018.
He also served as a Director at Cortria Corp.
and Vice President-Commercial Operations at Unimed Pharmaceuticals LLC.
Mr. King holds an undergraduate degree from the University of Surrey and an MBA from Manchester Business School.
Postes actifs de Richard A. King
| Sociétés | Poste | Début |
|---|---|---|
Prolynx LLC
 Prolynx LLC Miscellaneous Commercial ServicesCommercial Services Prolynx LLC engages in the development of proprietary drug delivery system for half-life extension of proteins, peptides, and small molecules. Its pipeline includes PLX038, PEG-PARP, IL-15, IL-2, PTH 1-34, GLP-1RA, and QMo IVT. The company was founded by Daniel V. Santi and Gary W. Ashley in 2010 and is headquartered in San Francisco, CA. | Directeur Général | 20/09/2022 |
Anciens postes connus de Richard A. King
| Sociétés | Poste | Fin |
|---|---|---|
| SPRUCE BIOSCIENCES, INC. | Directeur Général | 15/10/2021 |
| ADAMAS PHARMACEUTICALS, INC. | Directeur des opérations | 15/09/2018 |
The Scripps Research Institute
 The Scripps Research Institute Other Consumer ServicesConsumer Services The Scripps Research Institute is a private, non-profit research organizations that performs basic biomedical research in molecular & cellular biology, chemistry, immunology and neuroscience. They receive the majority of its funding from federal agencies such as the National Institutes of Health. The organization also partners with pharmaceutical companies and is affiliated with the Scripps hospital group. The organization was founded in 1955 and is headquartered in La Jolla, California. | Directeur des opérations | 01/04/2017 |
| TALPHERA, INC. | Directeur Général | 31/03/2015 |
Tercica, Inc.
 Tercica, Inc. Pharmaceuticals: MajorHealth Technology The Company's principal activity as a biopharmaceutical company is focused on the development and commercialization of products to improve endocrine health. Its first product, IncrelexTM (mecasermin {rDNA origin} injection), or recombinant human insulin-like growth factor-1 (rhIGF-1), is approved by the FDA for the treatment of severe Primary IGFD. The Company licensed the rights to develop, manufacture and commercialize Increlex from Genentech Inc. | President | 01/04/2009 |
Formation de Richard A. King
| University of Surrey | Undergraduate Degree |
| Manchester Business School | Masters Business Admin |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 2 |
|---|---|
| TALPHERA, INC. | Health Technology |
| SPRUCE BIOSCIENCES, INC. | Health Technology |
| Entreprise privées | 7 |
|---|---|
KOS Pharmaceuticals, Inc.
 KOS Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology KOS Pharmaceuticals, Inc. operates as pharmaceutical company that developed and commercialized proprietary prescription products for the treatment of chronic cardiovascular, metabolic and respiratory diseases. The company is founded by Daniel M. Bell and Michael Jaharis in 1988 and is headquartered in Cranbury, NJ. | Health Technology |
Solvay Pharmaceuticals, Inc.
 Solvay Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Solvay Pharmaceuticals, Inc manufactures pharmaceutical products. The company produces therapies for cardi-metabolic, gastroenterological, and neurological disorders. Its brands include Androgel, Klonopin, and ACEON drugs. Solvay Pharmaceuticals was founded by Ernest Solvay in 1863 and is located in Marietta, GA. | Health Technology |
Cortria Corp.
 Cortria Corp. Pharmaceuticals: MajorHealth Technology Cortria Corp. operates as a clinical-stage pharmaceutical company that focuses on developing medicines to fight cardiovascular disease. Its product is used for the treatment of dyslipidemia, an atherogenic disorder characterized by abnormal lipid levels in the bloodstream. The company was founded in August 2005 and is headquartered in Needham, MA. | Health Technology |
Tercica, Inc.
Tercica, Inc. Pharmaceuticals: MajorHealth Technology The Company's principal activity as a biopharmaceutical company is focused on the development and commercialization of products to improve endocrine health. Its first product, IncrelexTM (mecasermin {rDNA origin} injection), or recombinant human insulin-like growth factor-1 (rhIGF-1), is approved by the FDA for the treatment of severe Primary IGFD. The Company licensed the rights to develop, manufacture and commercialize Increlex from Genentech Inc. | Health Technology |
Adamas Pharmaceuticals LLC
 Adamas Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Adamas Pharmaceuticals, Inc. engages in discovery and development of chrono-synchronous therapies for chronic neurologic disorders. Its products include GOCOVRI, ADS-5012, ADS-4101, and Namzaric. GOCOVRI is indicated for the treatment of dyskinesia in patients with Parkinson’s disease receiving levodopa-based therapy. ADS-5102 is a treatment for walking impairment in patients with multiple sclerosis. ADS-401 treats partial onset seizures in patients with epilepsy. Namzaric is a drug treatment for moderate to severe Alzheimer's disease. The company was founded by Gregory T. Went on November 15, 2000 and is headquartered in Emeryville, CA. | Health Technology |
Unimed Pharmaceuticals LLC
 Unimed Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Unimed Pharmaceuticals, Inc. manufactured pharmaceutical products. It provided multiple indications in the therapeutic areas of cardiology, men's health, HIV and other infectious diseases. The company was founded in 1999 and was headquartered in Marietta, GA. | Health Technology |
Prolynx LLC
Prolynx LLC Miscellaneous Commercial ServicesCommercial Services Prolynx LLC engages in the development of proprietary drug delivery system for half-life extension of proteins, peptides, and small molecules. Its pipeline includes PLX038, PEG-PARP, IL-15, IL-2, PTH 1-34, GLP-1RA, and QMo IVT. The company was founded by Daniel V. Santi and Gary W. Ashley in 2010 and is headquartered in San Francisco, CA. | Commercial Services |
